Anti-vascular endothelial growth factor drugs combined with laser photocoagulation maintain retinal ganglion cell integrity in patients with diabetic macular edema: study protocol for a prospective, non-randomized, controlled clinical trial

被引:1
|
作者
Li, Xiangjun [1 ]
Li, Chunyan [2 ]
Huang, Hai [2 ]
Bai, Dan [1 ]
Wang, Jingyi [1 ]
Chen, Anqi [2 ]
Gong, Yu [2 ]
Leng, Ying [1 ]
机构
[1] Beihua Univ, Affiliated Hosp, Dept Ophthalmol, Jilin, Jilin, Peoples R China
[2] Beihua Univ, Affiliated Hosp, Dept Endocrinol, Jilin, Jilin, Peoples R China
关键词
choroidal thickness; diabetic macular edema; laser photocoagulation; retinal ganglion cell-inner plexiform layer thickness; retinal ganglion cells; retinal nerve fiber layer thickness; thickness of the macular area; vascular endothelial growth factor; visual acuity; VISUAL FUNCTION; RETINOPATHY; CONBERCEPT;
D O I
10.4103/1673-5374.382104
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The integrity of retinal ganglion cells is tightly associated with diabetic macular degeneration that leads to damage and death of retinal ganglion cells, affecting vision. The major clinical treatments for diabetic macular edema are anti-vascular endothelial growth factor drugs and laser photocoagulation. However, although the macular thickness can be normalized with each of these two therapies used alone, the vision does not improve in many patients. This might result from the incomplete recovery of retinal ganglion cell injury. Therefore, a prospective, non-randomized, controlled clinical trial was designed to investigate the effect of anti-vascular endothelial growth factor drugs combined with laser photocoagulation on the integrity of retinal ganglion cells in patients with diabetic macular edema and its relationship with vision recovery. In this trial, 150 patients with diabetic macular edema will be equally divided into three groups according to therapeutic methods, followed by treatment with anti-vascular endothelial growth factor drugs, laser photocoagulation therapy, and their combination. All patients will be followed up for 12 months. The primary outcome measure is retinal ganglion cell-inner plexiform layer thickness at 12 months after treatment. The secondary outcome measures include retinal ganglion cell-inner plexiform layer thickness before and 1, 3, 6, and 9 months after treatment, retinal nerve fiber layer thickness, best-corrected visual acuity, macular area thickness, and choroidal thickness before and 1, 3, 6, 9, and 12 months after treatment. Safety measure is the incidence of adverse events at 1, 3, 6, 9, and 12 months after treatment. The study protocol hopes to validate the better efficacy and safety of the combined treatment in patients with diabetic macula compared with the other two monotherapies alone during the 12-month follow-up period. The trial is designed to focus on clarifying the time-effect relationship between imaging measures related to the integrity of retinal ganglion cells and best-corrected visual acuity. The trial protocol was approved by the Medical Ethics Committee of the Affiliated Hospital of Beihua University with approval No. (2023)(26) on April 25, 2023, and was registered with the Chinese Clinical Trial Registry (registration number: ChiCTR2300072478, June 14, 2023, protocol version: 2.0).
引用
收藏
页码:923 / 928
页数:6
相关论文
共 24 条
  • [21] Photocoagulation or sham laser in addition to conventional anti-VEGF therapy in macular edema associated with TelCaps due to diabetic macular edema or retinal vein occlusion (TalaDME): a study protocol for a multicentric, French, two-group, non-commercial, active-control, observer-masked, non-inferiority, randomized controlled clinical trial
    Dupas, Benedicte
    Castro-Farias, Daniela
    Girmens, Jean-Francois
    Eginay, Ali
    Couturier, Aude
    Villeroy, Frederic
    Delyfer, Marie-Noelle
    Creuzot-Garcher, Catherine
    Giocanti-Auregan, Audrey
    Beral, Laurence
    Arndt, Carl
    Mesnard, Charles
    Vicaut, Eric
    Chaumet-Riffaud, Philippe
    Durand-Zaleski, Isabelle
    Paques, Michel
    TRIALS, 2024, 25 (01)
  • [22] Predictive factors for adherence to intravitreal anti-vascular endothelial growth factor therapy in Palestinian patients with diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration: a retrospective cohort study
    Hamza Abualhasan
    Ithar M Beshtawi
    Mohammad Noor
    Othman Mustafa
    Salem Hantoli
    BMC Ophthalmology, 25 (1)
  • [23] Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications Secondary Outcomes From the SCORE2 Randomized Clinical Trial
    Scott, Ingrid U.
    VanVeldhuisen, Paul C.
    Ip, Michael S.
    Blodi, Barbara A.
    Oden, Neal L.
    Altaweel, Michael
    Berinstein, Daniel M.
    JAMA OPHTHALMOLOGY, 2018, 136 (04) : 337 - 345
  • [24] Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib - Results of NCI/CTEP Protocol 9048
    Semrad, Thomas J.
    Groshen, Susan
    Luo, Chunqiao
    Pal, Sumanta
    Vaishampayan, Ulka
    Joshi, Monika
    Quinn, David, I
    Mack, Philip C.
    Gandara, David R.
    Lara, Primo N.
    KIDNEY CANCER, 2019, 3 (01) : 51 - 61